SCHEMBL15280845

SCHEMBL15280845

CC(C)(C)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)CC1OP(O)(=S)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
ENPP1 P22413 2/20 0.46
P2RY1 P47900 2/20 0.46
ADA P00813 1/20 0.46
ADORA1 P30542 2/20 0.44
DNPH1 O43598 1/20 0.43
PRKAB2 O43741 1/20 0.43
TRPM2 O94759 1/20 0.43
LDHA P00338 1/20 0.43
ADRB2 P07550 1/20 0.43
FBP1 P09467 1/20 0.43
SRC P12931 1/20 0.43
P2RY2 P41231 1/20 0.43
PRKAG1 P54619 1/20 0.43
PRKAA2 P54646 1/20 0.43
PDE4D Q08499 1/20 0.43
KCNH2 Q12809 1/20 0.43
PRKAA1 Q13131 1/20 0.43
PDE3A Q14432 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19887007 1.00 POLB (0.48) POLBENPP1P2RY1ADAADORA1
SCHEMBL15280904 0.92 POLB (0.51) POLBENPP1P2RY1ADORA1DNPH1
SCHEMBL15280819 0.92 POLB (0.51) POLBENPP1P2RY1ADORA1DNPH1
SCHEMBL24784386 0.92 POLB (0.51) POLBENPP1P2RY1ADORA1DNPH1
SCHEMBL19522883 0.91 POLB (0.46) POLBENPP1P2RY1ADAADORA1
SCHEMBL23205584 0.86 POLB (0.47) POLBENPP1P2RY1ADORA1DNPH1
SCHEMBL15280844 0.85 POLB (0.47) POLBENPP1P2RY1ADAADORA1
SCHEMBL19887008 0.85 POLB (0.47) POLBENPP1P2RY1ADAADORA1
SCHEMBL14534398 0.83 POLB (0.50) POLBENPP1P2RY1ADAADORA1
SCHEMBL12015128 0.83 POLB (0.50) POLBENPP1P2RY1ADAADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10731159-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-08-04 US disclosed
US-20200172903-A1 ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION OSAKA UNIVERSITY (JP) 2020-06-04 US disclosed
US-9803199-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-10-31 US disclosed
US-20160257951-A1 NOVEL LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-08 US disclosed
US-8987226-B2 Modified single-stranded polynucleotides DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-03-24 US disclosed
US-20130253038-A1 Modified Single-Stranded Polynucleotide DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257951-A1 NOVEL LIPID NPC1L1, CETP, LIPC POLB 394/4885ENPP1 736/4885P2RY1 1522/4885
US-20200172903-A1 ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION SNCA, ENO1, ENY2 POLB 89/4885ENPP1 13/4885P2RY1 1827/4885
US-10731159-B2 Cationic lipid CETP, NPC1L1, LIPA POLB 404/4885ENPP1 1066/4885P2RY1 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.